University of Sheffield researchers helped secure FDA approval for a new bone imaging method that could speed up osteoporosis ...

A study investigating the genetic determinants of fracture risk identified 15 genetic determinants of fracture, which also influenced bone mineral density. Among the clinical risk factors considered, ...

Bone loss in patients with kidney stone disease, particularly in men, has been underappreciated in clinical practice, according to investigators. Many patients with kidney stones concurrently have or ...

SMA children who can't walk have weaker upper leg bones than kids with cerebral palsy who are nonambulatory, a comparative ...

Credit: Getty Images In advanced CKD stages, patients are not only at risk of low bone mass but also of poor bone quality. Abnormalities in phosphorus, iPTH, and FGF-23 levels can increase the risk ...

Ultragenyx is developing setrusumab in pediatric and young adult patients across OI sub-types I, III and IV with two late-stage studies: the pivotal Phase 2/3 Orbit study and Phase 3 Cosmic study.

Setrusumab is a monoclonal antibody that inhibits sclerostin, a protein that negatively regulates bone development, allowing for new bone formation.

Ultragenyx Pharmaceutical said on Monday that late-stage studies showed its drug for a type of genetic bone disease failed to ...

Relations between bone parameters, physical exertion, and childhood fractures are complex. We aimed to estimate the associations between fracture history and bone mineral content (BMC) and areal bone ...

Bone loss in patients with kidney stone disease, particularly in men, has been underappreciated in clinical practice, according to investigators. Many patients with kidney stones concurrently have or ...